Ads
related to: asco guidelines 2022 parp inhibitors- About PARP Inhibitors
Learn About How Treatment Works.
Learn About Maintenance Therapy.
- Safety And Side Effects
Read Important Safety Information.
Learn More About A Treatment.
- Treatment Effectiveness
Read About How Treatment Works And
Its Benefits And Risks In Patients.
- Tablet Dosing Info
Learn About Tablet Dosing For
An Ovarian Cancer Treatment.
- First-Line Maintenance
Learn About First-Line Treatment.
Download Helpful Resources & Info.
- Talk To Your Doctor
Get Resources To Help Stay Informed
To Make Your Conversation Easier.
- About PARP Inhibitors
Search results
Results From The WOW.Com Content Network
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP). They are developed for multiple indications, including the treatment of heritable cancers. [1] Several forms of cancer are more dependent on PARP than regular cells, making PARP (PARP1, PARP2 etc.) an attractive target for cancer therapy.
Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer. [1] It is approved for use in China. [2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme.
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. [2] Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1).
Olaparib acts as an inhibitor of the enzyme poly ADP ribose polymerase (PARP), and is termed a PARP inhibitor. BRCA1/2 mutations may be genetically predisposed to development of some forms of cancer, and may be resistant to other forms of cancer treatment. However, these cancers sometimes have a unique vulnerability, as the cancer cells have ...
Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.
A substantial body of preclinical and clinical data has accumulated with PARP inhibitors in various forms of cancer. In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-associated lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and leading to the ...
Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).
Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer. [6] It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. [9]
Ad
related to: asco guidelines 2022 parp inhibitors